Advanced search
1 file | 298.91 KB Add to list

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

(2014) INFECTION. 42(4). p.757-762
Author
Organization
Abstract
ATRIPLA is licensed for use only in HIV-positive persons whose viral loads < 50 for a parts per thousand yen3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.
Keywords
EFAVIRENZ, TENOFOVIR, INITIAL TREATMENT, DOUBLE-BLIND, DISOPROXIL FUMARATE, EMTRICITABINE, ANTIRETROVIRAL THERAPY, TRIAL, INFECTION

Downloads

  • a survey of atripla.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 298.91 KB

Citation

Please use this url to cite or link to this publication:

MLA
Mocroft, A et al. “A Survey of ATRIPLA Use in Clinical Practice as First-line Therapy in HIV-positive Persons in Europe.” INFECTION 42.4 (2014): 757–762. Print.
APA
Mocroft, A, Reiss, P., Rakhmanova, A., Banhegyi, D., Phillips, A., De Wit, S., Ristola, M., et al. (2014). A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. INFECTION, 42(4), 757–762.
Chicago author-date
Mocroft, A, P Reiss, A Rakhmanova, D Banhegyi, AN Phillips, S De Wit, M Ristola, et al. 2014. “A Survey of ATRIPLA Use in Clinical Practice as First-line Therapy in HIV-positive Persons in Europe.” Infection 42 (4): 757–762.
Chicago author-date (all authors)
Mocroft, A, P Reiss, A Rakhmanova, D Banhegyi, AN Phillips, S De Wit, M Ristola, JD Lundgren, J Grarup, O Kirk, for EuroSIDA in EuroCOORD, and Linos Vandekerckhove. 2014. “A Survey of ATRIPLA Use in Clinical Practice as First-line Therapy in HIV-positive Persons in Europe.” Infection 42 (4): 757–762.
Vancouver
1.
Mocroft A, Reiss P, Rakhmanova A, Banhegyi D, Phillips A, De Wit S, et al. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. INFECTION. 2014;42(4):757–62.
IEEE
[1]
A. Mocroft et al., “A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe,” INFECTION, vol. 42, no. 4, pp. 757–762, 2014.
@article{5913705,
  abstract     = {ATRIPLA is licensed for use only in HIV-positive persons whose viral loads < 50 for a parts per thousand yen3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.},
  author       = {Mocroft, A and Reiss, P and Rakhmanova, A and Banhegyi, D and Phillips, AN and De Wit, S and Ristola, M and Lundgren, JD and Grarup, J and Kirk, O and EuroSIDA in EuroCOORD, for and Vandekerckhove, Linos},
  issn         = {0300-8126},
  journal      = {INFECTION},
  keywords     = {EFAVIRENZ,TENOFOVIR,INITIAL TREATMENT,DOUBLE-BLIND,DISOPROXIL FUMARATE,EMTRICITABINE,ANTIRETROVIRAL THERAPY,TRIAL,INFECTION},
  language     = {eng},
  number       = {4},
  pages        = {757--762},
  title        = {A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe},
  url          = {http://dx.doi.org/10.1007/s15010-014-0630-4},
  volume       = {42},
  year         = {2014},
}

Altmetric
View in Altmetric
Web of Science
Times cited: